About Johnson & Johnson (NYSE:JNJ)
Johnson & Johnson is a holding company, which is engaged in the research and development, manufacture and sale of a range of products in the healthcare field. It operates through three segments: Consumer, Pharmaceutical and Medical Devices. Its primary focus is products related to human health and well-being. The Consumer segment includes a range of products used in the baby care, oral care, skin care, over-the-counter pharmaceutical, women's health and wound care markets. The Pharmaceutical segment is focused on five therapeutic areas, including immunology, infectious diseases, neuroscience, oncology, and cardiovascular and metabolic diseases. The Medical Devices segment includes a range of products used in the orthopedic, surgery, cardiovascular, diabetes care and vision care fields. Its research facilities are located in the United States, Belgium, Brazil, Canada, China, France, Germany, India, Israel, Japan, the Netherlands, Singapore, Switzerland and the United Kingdom.
Industry, Sector and Symbol:
- Industry: Pharmaceuticals
- Sub-Industry: Pharmaceuticals
- Sector: Medical
- Symbol: NYSE:JNJ
- CUSIP: 47816010
- Web: www.jnj.com
- Debt-to-Equity Ratio: 0.36%
- Current Ratio: 1.32%
- Quick Ratio: 1.02%
Sales & Book Value:
- Trailing P/E Ratio: 19.33
- Forward P/E Ratio: 18.99
- P/E Growth: 2.8
- Annual Sales: $71.89 billion
- Price / Sales: 5.17
- Cash Flow: $8.29 per share
- Price / Cash: 16.67
- Book Value: $25.88 per share
- Price / Book: 5.34
- Annual Dividend: $3.36
- Dividend Yield: 2.4%
- Trailing EPS: $5.76
- Net Income: $16.54 billion
- Net Margins: 21.28%
- Return on Equity: 27.38%
- Return on Assets: 13.20%
- Employees: 126,400
- Outstanding Shares: 2,686,520,000
Frequently Asked Questions for Johnson & Johnson (NYSE:JNJ)
What is Johnson & Johnson's stock symbol?
Johnson & Johnson trades on the New York Stock Exchange (NYSE) under the ticker symbol "JNJ."
How often does Johnson & Johnson pay dividends? What is the dividend yield for Johnson & Johnson?
Johnson & Johnson declared a quarterly dividend on Thursday, October 19th. Investors of record on Tuesday, November 28th will be paid a dividend of $0.84 per share on Tuesday, December 12th. This represents a $3.36 dividend on an annualized basis and a dividend yield of 2.43%. The ex-dividend date of this dividend is Monday, November 27th. View Johnson & Johnson's Dividend History.
How were Johnson & Johnson's earnings last quarter?
Johnson & Johnson (NYSE:JNJ) posted its earnings results on Tuesday, October, 17th. The company reported $1.90 EPS for the quarter, topping the Thomson Reuters' consensus estimate of $1.80 by $0.10. The company earned $19.65 billion during the quarter, compared to analysts' expectations of $19.29 billion. Johnson & Johnson had a net margin of 21.28% and a return on equity of 27.38%. Johnson & Johnson's revenue was up 10.3% compared to the same quarter last year. During the same period last year, the company earned $1.68 EPS. View Johnson & Johnson's Earnings History.
When will Johnson & Johnson make its next earnings announcement?
What guidance has Johnson & Johnson issued on next quarter's earnings?
Johnson & Johnson updated its FY17 earnings guidance on Tuesday, October, 17th. The company provided earnings per share guidance of $7.25-7.30 for the period, compared to the Thomson Reuters consensus earnings per share estimate of $7.18. The company issued revenue guidance of $76.1-76.5 billion, compared to the consensus revenue estimate of $75.84 billion.
Where is Johnson & Johnson's stock going? Where will Johnson & Johnson's stock price be in 2017?
19 Wall Street analysts have issued 12 month target prices for Johnson & Johnson's stock. Their forecasts range from $110.00 to $165.00. On average, they expect Johnson & Johnson's share price to reach $143.56 in the next twelve months. View Analyst Ratings for Johnson & Johnson.
What are Wall Street analysts saying about Johnson & Johnson stock?
Here are some recent quotes from research analysts about Johnson & Johnson stock:
- 1. According to Zacks Investment Research, "Sales in J&J’s domestic Pharma segment have decelerated this year as a number of key growth drivers like Remicade and Concerta are facing competition. However, J&J is optimistic that sales growth will accelerate in 2H. We believe that new drugs like Xarelto, Stelara, Darzalex, and Imbruvica remain the key to growth. Meanwhile, share buybacks and restructuring initiatives should provide bottom-line support. J&J is also making rapid progress with its pipeline and line extensions. However, J&J’s shares have underperformed the industry this year so far. Headwinds like negative currency movement, generics, pricing pressure and soft global market conditions remain. Sluggish growth in the Consumer segment is also a concern. Meanwhile, HCV sales continue to decline amid intense competition. Estimates have remained mostly stable ahead of the Q3 results. J&J has a positive record of earnings surprises in recent quarters." (10/4/2017)
- 2. BTIG Research analysts commented, "Yesterday, we attended JNJ’s Pharma day held in New Brunswick, NJ. The overarching theme of the day was the expectation that the Pharma business outgrows the IMS projected ~5% 5-year CAGR for branded drugs. Our model is significantly below such expectations, as we have reported growth of ~6.5% during 2017 falling to ~3.6% in 2018 and essentially flat through 2020. Our numbers may prove conservative given that we do not currently include new drug launches of esketamine, guselkumab and sirukumab. We remain Neutral, as we think that the Oncology landscape is becoming more complicated and the Immunology portfolio may underperform internal expectations as a new class of oral drugs comes to market." (5/21/2017)
- 3. UBS AG analysts commented, "After making appropriate adjustments for year-over-year shipping day differences, JNJ's Q4 sales were up an impressive 9.5% in the U.S., and up 7.6% CC WW. Initial 2017 outlook calls for sales of $74.1-74.8 bil (up 4-5% CC) and EPS of $6.93-7.08 (including the AMO deal). As previewed, the guided range reflects greater impact from FX, and by our estimation a degree of conservatism. Given the continued strong growth of key Pharma franchises, management's potential to drive stable to improving margins, the ~$2.5 bil remaining repurchase authorization and other factors, we see flex and potential upside to management's initial 2017 outlook. We reiterate our Buy rating on top large-cap diversified pick JNJ, trimming our target from $142 to $141 due primarily to the ~$4.3 bil cash outlay for AMO, expected to close in 1Q17." (1/25/2017)
- 4. Jefferies Group LLC analysts commented, "With biosimilars and generics expected to drag the next few years, we expect JNJ will continue look to M&A to augment growth. Whilst this should ultimately drive better growth, we believe that investors will not reward the shares for this initially." (1/5/2017)
Who are some of Johnson & Johnson's key competitors?
Some companies that are related to Johnson & Johnson include Pfizer (PFE), Novartis AG (NVS), Merck & Company (MRK), Amgen (AMGN), Sanofi (SNY), Bristol-Myers Squibb Company (BMY), Novo Nordisk A/S (NVO), Abbott Laboratories (ABT), Eli Lilly and Company (LLY), GlaxoSmithKline PLC (GSK), Astrazeneca PLC (AZN), Celgene Corporation (CELG), GlaxoSmithKline plc (GSK), AstraZeneca plc (AZN), Shire PLC (SHPG), Shire PLC (SHP), Teva Pharmaceutical Industries Limited (TEVA) and Dr. Reddy's Laboratories Ltd (RDY).
Who are Johnson & Johnson's key executives?
Johnson & Johnson's management team includes the folowing people:
- Alex Gorsky, Chairman of the Board, Chief Executive Officer (Age 56)
- Dominic J. Caruso, Chief Financial Officer, Executive Vice President (Age 59)
- Peter M. Fasolo Ph.D., Chief Human Resource Officer, Executive Vice President (Age 54)
- Paulus A. Stoffels, Executive Vice President, Chief Scientific Officer (Age 55)
- Michael H. Ullmann, Executive Vice President, General Counsel (Age 58)
- Joaquin Duato, Executive Vice President, Worldwide Chairman - Pharmaceuticals (Age 54)
- Jorge S. Mesquita, Executive Vice President, Worldwide Chairman - Consumer (Age 55)
- Sandra E. Peterson, Executive Vice President - Group Worldwide Chairman (Age 58)
- Joseph Wolk, Vice President - Investor Relations
- Anne M. Mulcahy, Lead Independent Director (Age 64)
Who owns Johnson & Johnson stock?
Johnson & Johnson's stock is owned by a variety of of retail and institutional investors. Top institutional shareholders include Bank of New York Mellon Corp (1.36%), Ameriprise Financial Inc. (0.65%), Legal & General Group Plc (0.54%), Schwab Charles Investment Management Inc. (0.45%), Fisher Asset Management LLC (0.44%) and Swiss National Bank (401,574.66%). Company insiders that own Johnson & Johnson stock include Charles Prince, Dominic J Caruso, Gary J Pruden, Paulus Stoffels, Peter Fasolo and Ronald A Kapusta. View Institutional Ownership Trends for Johnson & Johnson.
Who sold Johnson & Johnson stock? Who is selling Johnson & Johnson stock?
Johnson & Johnson's stock was sold by a variety of institutional investors in the last quarter, including Boston Partners, Prudential Financial Inc., American Century Companies Inc., Macquarie Group Ltd., Schroder Investment Management Group, State of Tennessee Treasury Department, Artisan Partners Limited Partnership and California State Teachers Retirement System. Company insiders that have sold Johnson & Johnson company stock in the last year include Dominic J Caruso and Paulus Stoffels. View Insider Buying and Selling for Johnson & Johnson.
Who bought Johnson & Johnson stock? Who is buying Johnson & Johnson stock?
Johnson & Johnson's stock was acquired by a variety of institutional investors in the last quarter, including Stifel Financial Corp, APG Asset Management N.V., Assenagon Asset Management S.A., Sanders Capital LLC, Janus Henderson Group PLC, Capital International Investors, Schwab Charles Investment Management Inc. and Caisse DE Depot ET Placement DU Quebec. View Insider Buying and Selling for Johnson & Johnson.
How do I buy Johnson & Johnson stock?
Shares of Johnson & Johnson can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Johnson & Johnson's stock price today?
One share of Johnson & Johnson stock can currently be purchased for approximately $138.01.
How big of a company is Johnson & Johnson?
Johnson & Johnson has a market capitalization of $370.73975 billion and generates $71.89 billion in revenue each year. The company earns $16.54 billion in net income (profit) each year or $5.76 on an earnings per share basis. Johnson & Johnson employs 126,400 workers across the globe.
How can I contact Johnson & Johnson?
Johnson & Johnson's mailing address is ONE JOHNSON & JOHNSON PLZ, NEW BRUNSWICK NJ, 08933. The company can be reached via phone at 732-524-0400.
MarketBeat Community Rating for Johnson & Johnson (NYSE JNJ)MarketBeat's community ratings are surveys of what our community members think about Johnson & Johnson and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.
Analysts' Consensus Rating for Johnson & Johnson (NYSE:JNJ) (How are Consensus Ratings Calculated?)
MarketBeat calculates consensus analyst ratings for company stocks using the most recent rating from each brokerage that has rated a stock within the last twelve months. Since brokers often use different ratings systems, each rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months.
MarketBeat will no longer include ratings and price target data in its consensus calculation if a broker drops coverage and MarketBeat has received a report that coverage was dropped. Ratings from certain research firms that issue ratings using purely quantitative methods (such as Zacks, Vetr and ValuEngine) are not included in consensus calculations. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
|Ratings Breakdown: ||4 Sell Ratings, 5 Hold Ratings, 10 Buy Ratings, 0 Strong Buy Ratings|
|Consensus Rating:||Hold (Score: 2.32)|
|Consensus Price Target: ||$143.56 (3.83% upside)|
Consensus Price Target History for Johnson & Johnson (NYSE:JNJ)
Analysts' Ratings History for Johnson & Johnson (NYSE:JNJ)
(Data available from 11/20/2015 forward)
|Date||Firm||Action||Rating||Price Target||Impact on Share Price||Details|
|10/23/2017||Citigroup Inc.||Boost Price Target||Buy||$140.00 -> $149.00||N/A|
|10/19/2017||Credit Suisse Group||Set Price Target||Outperform||$147.00 -> $154.00||N/A|
|10/16/2017||Jefferies Group LLC||Boost Price Target||Buy||$157.00 -> $160.00||N/A|
|10/18/2017||Barclays PLC||Boost Price Target||Equal Weight||$140.00 -> $148.00||N/A|
|10/18/2017||Cowen and Company||Reiterated Rating||Outperform||$147.00 -> $155.00||N/A|
|10/18/2017||Morgan Stanley||Reiterated Rating||Hold||$140.00 -> $145.00||N/A|
|10/18/2017||Argus||Boost Price Target||Buy -> Positive||$145.00 -> $165.00||N/A|
|10/18/2017||Wells Fargo & Company||Reiterated Rating||Outperform||$149.00 -> $155.00||N/A|
|10/18/2017||BMO Capital Markets||Reiterated Rating||Outperform -> Positive||$145.00 -> $152.00||N/A|
|10/18/2017||Stifel Nicolaus||Boost Price Target||Hold -> Hold||$140.00 -> $142.00||N/A|
|10/18/2017||Royal Bank Of Canada||Boost Price Target||Outperform -> Outperform||$144.00 -> $147.00||N/A|
|10/18/2017||Leerink Swann||Reiterated Rating||Outperform -> Outperform||$150.00 -> $165.00||N/A|
|10/4/2017||Piper Jaffray Companies||Reiterated Rating||Hold||$120.00||Low|
|9/20/2017||Goldman Sachs Group, Inc. (The)||Downgrade||Neutral -> Sell||$125.00 -> $130.00||Low|
|8/16/2017||J P Morgan Chase & Co||Boost Price Target||Overweight||$140.00 -> $148.00||Low|
|7/21/2017||Alembic Global Advisors||Downgrade||Neutral -> Underweight||Low|
|7/21/2017||Atlantic Securities||Downgrade||Neutral -> Underweight||$113.00||Low|
|7/21/2017||BTIG Research||Downgrade||Neutral -> Sell||$110.00||Low|
|11/28/2016||Bank of America Corporation||Reiterated Rating||Hold||$126.00||N/A|
|10/23/2016||Societe Generale||Reiterated Rating||Hold||$116.00||N/A|
|8/19/2016||Deutsche Bank AG||Reiterated Rating||Buy||$142.00||N/A|
|5/20/2016||Raymond James Financial, Inc.||Reiterated Rating||Outperform||$120.00||N/A|
|5/20/2016||Standpoint Research||Initiated Coverage||Sell||$94.00||N/A|
|1/27/2016||Independent Research GmbH||Set Price Target||Neutral||$108.00||N/A|
Earnings History and Estimates Chart for Johnson & Johnson (NYSE:JNJ)
Earnings History by Quarter for Johnson & Johnson (NYSE JNJ)
(Data available from 1/1/2011 forward)
|Date||Quarter||Consensus Estimate||Actual EPS||Revenue Estimate||Actual Revenue||Release Link||Conference Call||Details|
|10/17/2017||Q3 2017||$1.80||$1.90||$19.29 billion||$19.65 billion||View||N/A|
|7/18/2017||Q2 2017||$1.79||$1.83||$18.94 billion||$18.84 billion||View||N/A|
|4/18/2017||Q1 17||$1.77||$1.83||$18.02 billion||$17.77 billion||View||N/A|
|1/24/2017||Q416||$1.56||$1.58||$18.28 billion||$18.10 billion||View||N/A|
|10/18/2016||Q316||$1.65||$1.68||$17.71 billion||$17.80 billion||View||Listen|
|7/19/2016||Q216||$1.68||$1.74||$17.98 billion||$18.50 billion||View||Listen|
|4/19/2016||Q116||$1.65||$1.68||$17.50 billion||$17.50 billion||View||Listen|
|1/26/2016||Q415||$1.42||$1.44||$17.88 billion||$17.80 billion||View||Listen|
|10/13/2015||Q315||$1.45||$1.49||$17.47 billion||$17.10 billion||View||Listen|
|7/14/2015||Q215||$1.69||$1.71||$17.76 billion||$17.80 billion||View||Listen|
|4/14/2015||Q115||$1.54||$1.56||$17.31 billion||$17.37 billion||View||Listen|
|1/20/2015||Q414||$1.25||$1.27||$18.59 billion||$18.30 billion||View||Listen|
|10/14/2014||Q314||$1.42||$1.50||$18.41 billion||$18.50 billion||View||Listen|
|7/15/2014||Q214||$1.54||$1.66||$18.86 billion||$19.50 billion||View||N/A|
|4/15/2014||Q114||$1.48||$1.54||$18.00 billion||$18.10 billion||View||N/A|
|1/21/2014||Q413||$1.20||$1.24||$17.95 billion||$18.40 billion||View||N/A|
|10/15/2013||Q313||$1.32||$1.36||$17.46 billion||$17.60 billion||View||N/A|
|7/16/2013||Q2 2013||$1.39||$1.48||$17.71 billion||$17.90 billion||View||N/A|
|4/16/2013||Q1 2013||$1.41||$1.44||$17.46 billion||$17.50 billion||View||N/A|
|1/22/2013||Q4 2012||$1.17||$1.19||$17.67 billion||$17.60 billion||View||N/A|
Earnings Estimates for Johnson & Johnson (NYSE:JNJ)
2017 EPS Consensus Estimate: $7.08
2018 EPS Consensus Estimate: $7.99
(Data provided by Zacks Investment Research)
|Quarter||Number of Estimates||Low Estimate||High Estimate||Average Estimate|
Current Dividend Information for Johnson & Johnson (NYSE:JNJ)
|Dividend Growth:||6.70% (3 Year Average)|
|Payout Ratio:||58.33% (Trailing 12 Months of Earnings) |
46.15% (Based on This Year's Estimates)
42.80% (Based on Next Year's Estimates)
|Track Record:||54 Years of Consecutive Dividend Growth|
Dividend History by Quarter for Johnson & Johnson (NYSE JNJ)
(Data available from 1/1/2013 forward)
|Announced||Period||Amount||Yield||Ex-Dividend Date||Record Date||Payable Date|
Insider Trading and Institutional Ownership History for Johnson & Johnson (NYSE JNJ)
Insider Ownership Percentage: 0.19%
Institutional Ownership Percentage: 65.61%
Insider Trades by Quarter for Johnson & Johnson (NYSE JNJ)
(Data available from 1/1/2013 forward)
|Transaction Date||Insider Name||Title||Buy/Sell||Number of Shares||Average Share Price||Total Transaction||Details|
|7/24/2017||Paulus Stoffels||VP||Sell||102,692||$133.14||$13,672,412.88|| |
|7/20/2017||Dominic J Caruso||VP||Sell||82,591||$136.72||$11,291,841.52|| |
|2/15/2017||Paulus Stoffels||VP||Sell||22,000||$117.29||$2,580,380.00|| |
|10/21/2016||Charles Prince||Director||Buy||875||$114.11||$99,846.25|| |
|7/26/2016||Dominic J Caruso||VP||Sell||41,146||$125.01||$5,143,661.46|| |
|7/22/2016||Ronald A Kapusta||CAO||Sell||2,935||$125.01||$366,904.35|| |
|6/7/2016||Gary J Pruden||VP||Sell||9,735||$116.03||$1,129,552.05|| |
|6/7/2016||Ronald A Kapusta||CAO||Sell||3,000||$115.79||$347,370.00|| |
|5/10/2016||Ronald A Kapusta||CAO||Sell||3,957||$114.77||$454,144.89|| |
|2/17/2016||Paulus Stoffels||insider||Sell||125,000||$102.43||$12,803,750.00|| |
|2/3/2016||Peter Fasolo||VP||Sell||151,385||$104.12||$15,762,206.20|| |
|10/23/2015||Ronald A. Kapusta||CAO||Sell||6,239||$99.68||$621,903.52|| |
|6/2/2015||Charles Prince||Director||Buy||2,500||$99.22||$248,050.00|| |
|4/28/2015||Paulus Stoffels||Insider||Sell||187,250||$100.73||$18,861,692.50|| |
|9/10/2014||James Cullen||Director||Sell||2,446||$104.12||$254,677.52|| |
|5/5/2014||Stephen Cosgrove||Insider||Sell||22,000||$100.05||$2,201,100.00|| |
|3/14/2014||Peter Fasolo||VP||Sell||6,824||$93.15||$635,655.60|| |
|8/14/2013||Stephen Cosgrove||Insider||Sell||17,200||$91.39||$1,571,908.00|| |
|8/5/2013||Michael Ullmann||VP||Sell||16,140||$93.68||$1,511,995.20|| |
|7/25/2013||Paulus Stoffels||Insider||Sell||45,440||$92.40||$4,198,656.00|| |
|7/18/2013||Dominic J Caruso||CFO||Sell||30,000||$90.31||$2,709,300.00|| |
|11/12/2012||James Cullen||Director||Sell||13,900||$69.70||$968,830.00|| |
Latest Headlines for Johnson & Johnson (NYSE JNJ)
Johnson & Johnson (NYSE JNJ) Chart for Monday, November, 20, 2017